Oxyphenonium Bromide represents a pharmaceutically optimised salt form in which counter-ion selection modifies the physicochemical properties of the parent molecule without altering its core pharmacophore or intrinsic pharmacodynamic activity. The crystal lattice energy of Oxyphenonium Bromide determines its thermodynamic stability, dissolution behaviour, and susceptibility to polymorphic transformation under manufacturing process conditions. PDE assessment for Oxyphenonium Bromide in shared manufacturing facilities is based on the pharmacological activity of the parent active moiety, with the MACO calculation adjusted using the molecular weight ratio of free base or acid to salt form.
Study duration uncertainty factor F3 in PDE derivation for Oxyphenonium Bromide compensates for the data gap between the duration of available toxicology studies and the chronic lifetime pharmaceutical exposure scenario.
